Update on Targeted Therapy in Medullary Thyroid Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor comprising 2-4% of thyroid cancers.
• Activating mutations in the rearranged during transfection (RET) proto-oncogene drive all inherited and about half of sporadic MTC cases.
• RET-targeting tyrosine kinase inhibitors (TKIs) offer systemic therapy for metastatic and progressive MTC.

Purpose of the Study:

• To review current therapeutic strategies for MTC.
• To discuss challenges in MTC treatment, including TKI resistance and alternative molecular drivers.
• To highlight the need for novel therapeutic targets and improved understanding of resistance mechanisms.

Main Methods:

• Literature review of MTC pathogenesis and treatment.
• Analysis of clinical data regarding TKI efficacy and resistance.
• Exploration of molecular mechanisms underlying MTC development and progression.

Main Results:

• RET mutations are key drivers in MTC, making RET-targeted TKIs effective for many patients.
• Acquired resistance to TKIs and alternative oncogenic drivers (e.g., RAS mutations) present significant therapeutic challenges.
• Limited treatment options exist for patients with resistant or non-RET-driven MTC.

Conclusions:

• While RET-targeted TKIs have improved MTC treatment, resistance remains a critical issue.
• Further research into mechanisms of TKI resistance and identification of novel therapeutic targets are essential.
• Improved understanding and new therapeutic strategies are needed to enhance outcomes for all MTC patients.